Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Cushing's syndrome Stories

2012-02-17 16:02:00

SILVER SPRING, Md., Feb. 17, 2012 /PRNewswire-USNewswire/ -- Today, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing's syndrome. This drug was approved for use in patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by...

2012-02-16 06:30:00

EXTON, Pa., Feb. 16, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that data from the pivotal study for their orphan drug Plenadren® (hydrocortisone, modified release tablet) were published in the Journal of Clinical Endocrinology and Metabolism (JCEM), a leading scientific journal for endocrinology. Plenadren was recently granted European Marketing Authorization for treatment of adrenal insufficiency in adults. The authors described results showing that the...

2011-11-22 08:28:01

(Ivanhoe Newswire) — Cushing´s disease is a hormone disorder that causes many symptoms, such as high blood pressure, fat accumulation, osteoporosis and ultimately ending in death. It is caused by a tumor in the anterior pituitary gland that secretes excess amounts of adrenocorticotrophic hormone (ACTH). The only treatment is removal of the tumor, however, researchers have found a new treatment for these reoccurring tumors. Researchers, led by Shlomo Melmed, at Cedars-Sinai...

2011-11-21 23:10:25

Cushing disease is a hormone disorder that causes a diverse array of symptoms, including fat accumulation, high blood pressure, osteoporosis, muscle wasting, and ultimately death. It is caused by a tumor in the anterior pituitary gland that results in the secretion of excess amounts of adrenocorticotropic hormone (ACTH). Treatment options are essentially limited to surgical resection. However, tumors commonly recur, meaning that new treatment options are needed. A team of researchers, led by...

2011-11-15 07:00:00

EXTON, Pa., Nov. 15, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it completed its acquisition of DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy. The acquisition of Duocort Pharma AB further expands ViroPharma's orphan disease commercial product pipeline. ViroPharma has paid an upfront closing cost of 220 million Swedish kroner (SEK) or $33.6 million in US dollars (USD)....

2011-11-07 06:00:00

HELSINGBORG, Sweden and EXTON, Pa., Nov. 7, 2011 /PRNewswire/ -- The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren® (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years. Developed by DuoCort Pharma, Plenadren®...

2011-10-27 06:00:00

EXTON, Pa., Oct. 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it has signed a definitive agreement to acquire DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy. The acquisition of DuoCort Pharma AB will further expand ViroPharma's orphan disease commercial product pipeline. The company intends to discuss this acquisition on its third quarter financial results conference call...

2011-05-10 15:32:18

A common, tiny tropical fish plays a key role in a new model for Cushing disease, giving researchers a powerful tool to conduct extensive searches for effective treatments for this serious hormonal disorder, testing up to 300 drugs weekly. The model "“ published online on May 2 by the Proceedings of the National Academy of Sciences -- was created in the laboratory of Shlomo Melmed, MD, dean of the medical faculty at Cedars-Sinai Medical Center, by his research team led by Ning-Ai Liu,...

2011-03-24 00:00:27

Corcept Therapeutics (NASDAQ: CORT) released their final Phase 3 data for Corlux in mid-January, concluding a successful clinical trial. The next anticipated milestone is submission of the New Drug Application to the U.S. Food and Drug Administration. Corcept Therapeutics plans to submit, with a priority review (6-months), end of first quarter. The FDA determines within 45 days after submission to grant priority review. New York, NY (Vocus/PRWEB) March 22, 2011 After Corcept Therapeutics...

2010-09-22 00:27:00

EAST HANOVER, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Novartis Pharmaceuticals Corporation ("Novartis") (NYSE: NVS) announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal(1). Results will be presented at the 14th Congress of the European Neuroendocrine...